Page last updated: 2024-12-05
bromophos
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
bromophos: minor descriptor (72-83); on-line & Index Medicus search ORGANOTHIOPHOSPHORUS COMPOOUNDS (72) & INSECTICIDES (72) & INSECTICIDES, ORGANOTHIOPHOSPHATE (73-83); structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 16422 |
| CHEMBL ID | 2104572 |
| CHEBI ID | 82104 |
| SCHEMBL ID | 118537 |
| MeSH ID | M0262580 |
Synonyms (109)
| Synonym |
|---|
| BIDD:ER0070 |
| bromophos-methyl |
| oms 658 |
| o,5-dichlorophenyl) phosphorothioate |
| thiophosphate de o,5-dichlorophenyle |
| nsc-527602 |
| bromophos |
| nexion lc 40 |
| cx99 |
| nexion |
| nexion 40 |
| el 400 |
| bromovur |
| wln: gr dg be eops&o1&o1 |
| 4-bromo-2,5-dichlorophenyl dimethyl phosphorothionate |
| cela s 1942 |
| o-(4-bromo-2,-dicloro-fenil)-o,o-dimetil-monotiofosfato |
| drillzid |
| nsc527602 |
| s 1942 |
| o,5-dichloro-4-bromophenyl) thiophosphate |
| 2104-96-3 |
| oms658 |
| netal |
| mexion |
| o-(4-broom-2,o-dimethyl-monothiofosfaat |
| ent 27,162 |
| phosphorothioic acid,5-dichlorophenyl) o,o-dimethyl ester |
| bromofos |
| o-(4-bromo-2,o-dimethyl phosphorothioate |
| brofene |
| o,5-dichloro-4-bromophenyl) phosphorothioate |
| nexagan |
| phenol,5-dichloro-, o-ester with o,o-dimethyl phosphorothioate |
| o-(4-brom-2,o-dimethyl-monothiophosphat |
| bromofos-methyl |
| brophene |
| phosphorothioic acid, o-(4-bromo-2,5-dichlorophenyl) o,o-dimethyl ester |
| o,o-dimethyl o-(4-bromo-2,5-dichlorophenyl) phosphorothioate |
| bromophos [bsi:iso] |
| o-(4-bromo-2,5-dichlorophenyl) o,o-dimethyl monothiophosphate |
| phenol, 4-bromo-2,5-dichloro-, o-ester with o,o-dimethyl phosphorothioate |
| phosphorothioic acid o-(4-bromo-2,5-dichlorophenyl) o,o-dimethyl ester |
| caswell no. 114e |
| nexion lc40 |
| epa pesticide chemical code 008706 |
| hsdb 6573 |
| o-(4-bromo-2,5-dicloro-fenil)-o,o-dimetil-monotiofosfato [italian] |
| omexan |
| nsc 527602 |
| bromo-phos-methyl |
| o,o-dimethyl o-(2,5-dichloro-4-bromophenyl) phosphorothioate |
| o-(4-broom-2,5-dichloor-fenyl)-o,o-dimethyl-monothiofosfaat [dutch] |
| einecs 218-277-3 |
| sovinexion |
| o,o-dimethyl o-(2,5-dichloro-4-bromophenyl) thiophosphate |
| thiophosphate de o,o-dimethyle et de o-4-bromo-2,5-dichlorophenyle [french] |
| o-(4-bromo-2,5-dichlorophenyl) o,o-dimethyl phosphorothioate |
| bruomophos [russian] |
| o,o-dimethyl-o-(2,5-dichloro-4-bromophenyl)phosphorothioate |
| metabrom |
| nexion 5g |
| ai3-27162 |
| o-(4-brom-2,5-dichlor-phenyl)-o,o-dimethyl-monothiophosphat [german] |
| s-1942 , |
| monsanto cp 51969 |
| o,o-dimethyl-o-2,5-dichloro-4-bromophenyl phosphorothionate |
| oms-658 |
| brn 1988276 |
| o,o-dimethyl-o-(2,5-dichlor-4-bromphenyl)-thionophosphat [german] |
| bromofos [inn] |
| bromofosum [inn-latin] |
| C18965 |
| o,o-dimethyl-o-(2,5-dichlor-4-bromphenyl)-thionophosphat |
| thiophosphate de o,o-dimethyle et de o-4-bromo-2,5-dichlorophenyle |
| bromofosum |
| unii-74a4tne8c3 |
| o-(4-bromo-2,5-dicloro-fenil)-o,o-dimetil-monotiofosfato |
| 74a4tne8c3 , |
| o-(4-brom-2,5-dichlor-phenyl)-o,o-dimethyl-monothiophosphat |
| o-(4-broom-2,5-dichloor-fenyl)-o,o-dimethyl-monothiofosfaat |
| bruomophos |
| dtxsid1041683 , |
| cas-2104-96-3 |
| dtxcid9021683 |
| NCGC00255569-01 |
| tox21_301918 |
| chebi:82104 , |
| CHEMBL2104572 |
| FT-0603590 |
| AKOS015888390 |
| SCHEMBL118537 |
| o-4-bromo-2,5-dichlorophenyl o,o-dimethyl phosphorothioate |
| bromofos [jan] |
| bromophos [iso] |
| bromofos [hsdb] |
| bromophos [mi] |
| o-(4-bromo-2,5-dichlorophenyl) o,o-dimethyl thiophosphate # |
| SR-01000944390-1 |
| sr-01000944390 |
| bromophos-methyl, pestanal(r), analytical standard |
| bromophos-methyl 10 microg/ml in cyclohexane |
| bromophos-methyl 100 microg/ml in cyclohexane |
| J-013800 |
| bromophos methyl |
| Q2926019 |
| (4-bromo-2,5-dichlorophenoxy)-dimethoxy-sulfanylidene-lambda5-phosphane |
| o-(4-bromo-2,5-dichlorophenyl)-o,o-dimethyl phosphorothioate |
| CAA10496 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pretreatment with Aroclor 1254 or beta-naphthoflavone (beta-NF) did not alter the LD50 of 1-NN." | ( 1-Nitronaphthalene toxicity in rat lung and liver: effects of inhibiting and inducing cytochrome P450 activity. Carthew, P; Dinsdale, D; Verschoyle, RD; Wolf, CR, 1993) | 0.29 |
| " EBp is 24-fold more toxic (LD50 = 91 +/- 14 mg/kg body wt) than Bp (LD50 = 2218 +/- 195 mg/kg body wt) and only EBp produced characteristic tremors and lacrimation." | ( Neurotoxicity and pattern of acetylcholinesterase inhibition in the brain regions of rat by bromophos and ethylbromophos. Karanth, S; Santhoshkumar, P; Shivanandappa, T, 1996) | 0.51 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dose-response studies (50-4000 mg/kg body weight, 24 h exposure) showed that plasma cholinesterase was most sensitive to inhibition in vivo, followed by the brain and erythrocyte acetylcholinesterase." | ( Response of blood and brain cholinesterase to dermal exposure of bromophos in the rat. Joseph, P; Krishnakumari, MK; Shivanandappa, T, 1988) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| organic thiophosphate | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (24)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 63.2609 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 79.6407 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 24.5412 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 68.5896 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 76.9588 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| AR protein | Homo sapiens (human) | Potency | 41.4435 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743063 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 37.8316 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 30.6379 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 61.6448 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 58.5172 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 12.1972 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 45.0232 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID743069; AID743075; AID743077 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 54.9410 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 43.6412 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 24.3365 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 68.5896 | 0.0016 | 28.0151 | 77.1139 | AID1259385 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 43.6412 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 61.1306 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 54.4827 | 0.0006 | 27.2152 | 1,122.0200 | AID743219 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 61.1306 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 69.9313 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 61.1306 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 54.4827 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
| Ataxin-2 | Homo sapiens (human) | Potency | 54.4827 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (141)
Molecular Functions (40)
Ceullar Components (27)
Research
Studies (22)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 11 (50.00) | 18.7374 |
| 1990's | 7 (31.82) | 18.2507 |
| 2000's | 1 (4.55) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 23.70
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.70) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 2 (8.33%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||